Multiple Myeloma as a Chronic Disease

Leslie Lauersdorf, ARNP

Multiple Myeloma as a Chronic Disease

ASH 2019 – Multiple Myeloma

Moffitt Cancer Center
Tampa Bay, FL

As multiple myeloma moves toward being considered a chronic disease, nurses and navigators have new considerations to keep in mind when treating their patients.

Related Items

LCAR-B38M CAR-T Therapy Yields High Complete Response Rate and Survival Time

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

GRIFFIN Study: Daratumumab Deepens Responses Over Time

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

Baseline PET/CT Findings Have Prognostic Value in Newly Diagnosed Multiple Myeloma

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

Daratumumab plus Standard of Care Improves Overall Survival in ALCYONE Trial

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

Daratumumab Maintenance Deepens Responses, Survival in Multiple Myeloma

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

Benefit Shown for Daratumumab plus Carfilzomib + Dexamethasone

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

Study Moves CAR-T Therapy Forward in Myeloma

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

What is Minimal Residual Disease (MRD) Negativity?

By Leslie Lauersdorf, ARNP

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

In Routine Practice, Ixazomib Regimen Mirrors Efficacy of Clinical Trial

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma

In Relapsed or Refractory Myeloma, Addition of Elotuzumab to Lenalidomide + Dexamethasone Improves Outcomes with No Detriment to Quality of Life

American Society of Hematology (ASH)

ASH 2019 – Multiple Myeloma